Drug Profile


Alternative Names: MTBVAC 01

Latest Information Update: 18 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Biofabri; University of Zaragoza
  • Developer Biofabri
  • Class Attenuated vaccines; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Tuberculosis

Most Recent Events

  • 12 Oct 2016 Aeras, Biofabri, the University of Zaragoza and the South African Tuberculosis Vaccine Initiative plan a phase Ib/IIa trial for Tuberculosis (Prevention, In adults) in USA and South Africa (Intradermal, Injection) (NCT02933281)
  • 02 Aug 2016 Phase-I development is ongoing in Switzerland
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Tuberculosis(In volunteers) in Switzerland (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top